investments-companies-company-17.html
Novo Annual Report 2015
18 / 72
x ellia pharmaceuticals is a specialty pharmaceutical
company
that produces injectable anti-infective treatments against serious and often life-threatening infections.
xellia
?s range of anti-infective treatments combats most types of bacterial infections and certain fungal diseases. some of these products can be used against antibiotic-resistant strains too. the
company
is the market-leading supplier of the anti-infectives, vancomycin and colistimethate sodium. vancomycin is used in the treatment of serious, life-threatening infections that have been unresponsive to other antibiotics. colistimethate sodium is primarily used to treat lung infections, especially in patients with cystic fibrosis. in a world where the prevalence of multi- resistant infections is becoming more frequent,
xellia
?s portfolio of treatments offers a vital contribution to curing illnesses and saving lives.
xellia
has sales in more than 70 countries to more than 700 customers. the
company
is continually developing and expanding its product range to meet new treatment needs and customer requirements. this includes the development of new dosage forms.
xellia
also offers contract
manufacturing
services and custom synthesis for clinical trial material supply.
xellia
founded in 1903 in norway headquartered in copenhagen, denmark, with
manufacturing
in hungary, the us and china private
company
fully owned by novo a/s (acquired in 2013) market leader in non-beta lactam anti- infectives, based on fermentation and aseptic
manufacturing
technologies revenue 2015: usd 220 million board member representing novo a/s: steen riisgaard, chairman and aleks engel, asset director www.
xellia
.com news
xellia
announced the expansion of its raleigh, nc site to enable the relocation of its north american headquarters from grayslake, illinois. acquired large finished dosage form
manufacturing
plant in cleveland ohio. ?
xellia
?s acquisition of a key
manufacturing
facility in cleveland ohio in 2015 is a great leap forward for the
company
. as
xellia
?s second
manufacturing
site in the us, this greatly expands its global
manufacturing
footprint, allowing it to meet the growing demand for sterile injectable products locally in the us, as well as address drug shortages of critical life-saving antibiotics globally.? carl-åke carlsson ceo novo a/s 18 large investments
hearing-sonion-aid-19.html
